Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Winokur

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Psychopharmacology|July 14, 2005
Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depressionMartin P Szuba, Jay D Amsterdam, Antonio T Fernando, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomniaAndrew Winokur, Nicholas A DeMartinis, Daniel P McNally, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 2, 2004
Amantadine for weight gain associated with olanzapine treatmentWalter Deberdt, Andrew Winokur, Patrizia A Cavazzoni, et al.
The Journal of Clinical Psychiatry|September 23, 2022
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant DepressionDavid J Williamson, Jagadish P Gogate, Jennifer K Kern Sliwa, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 11, 2003
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depressionMark S Kramer, Andrew Winokur, Jeffrey Kelsey, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
The Journal of Clinical Psychiatry|January 8, 2013
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorderGeorge I Papakostas, Ottavio V Vitolo, Waguih W Ishak, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Psychopharmacology|July 14, 2005
Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depressionMartin P Szuba, Jay D Amsterdam, Antonio T Fernando, et al.
The Journal of Clinical Psychiatry|December 9, 2003
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomniaAndrew Winokur, Nicholas A DeMartinis, Daniel P McNally, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 2, 2004
Amantadine for weight gain associated with olanzapine treatmentWalter Deberdt, Andrew Winokur, Patrizia A Cavazzoni, et al.
The Journal of Clinical Psychiatry|September 23, 2022
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant DepressionDavid J Williamson, Jagadish P Gogate, Jennifer K Kern Sliwa, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 11, 2003
Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depressionMark S Kramer, Andrew Winokur, Jeffrey Kelsey, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
The Journal of Clinical Psychiatry|January 8, 2013
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorderGeorge I Papakostas, Ottavio V Vitolo, Waguih W Ishak, et al.
JAMA Psychiatry|June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Madhukar H Trivedi, Adam Janik, et al.
Pageof 2